Information Provided By:
Fly News Breaks for September 28, 2015
VRTX
Sep 28, 2015 | 07:38 EDT
Argus upgraded Vertex to Buy with a $126 price target. Argus upgraded shares based on recent weakness and said the company's earnings outlook has become more transparent over the past year based on positive results from new cystic fibrosis drugs, including Orkambi, which has blockbuster potential.